Publications by authors named "Roy Matining"

Claim this Profile
W
Wilms' tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP.
Ayana E Morales, Ruby Gumenick, Caitlyn M Genovese, Yun Yeong Jang, Ariene Ouedraogo, Roy M Matining

PLoS Pathog· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS).
David L Wyles, Minhee Kang, Roy M Matining, Robert L Murphy, Marion G Peters

Open Forum Infect Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Clinical Trial of Human Papillomavirus Test-and-Treat as Compared to Cytology-Based Screening for Prevention of Cervical Cancer Among Women With Human Immunodeficiency Virus: AIDS Clinical Trials Group Protocol A5282.
Timothy Wilkin, Huichao Chen, Vikrant Sahasrabuddhe, Roy Matining, Rosie Mngqibisa

Clin Infect Dis· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
Claudia Hawkins, Minhee Kang, Debika Bhattacharya, Gavin Cloherty, Mary Kuhns, Roy Matining

AIDS· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).
David L Wyles, Minhee Kang, Roy M Matining, Robert L Murphy, Marion G Peters

Open Forum Infect Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
Susan E Krown, Carlee B Moser, Patrick MacPhail, Roy M Matining, Catherine Godfrey

Lancet· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS).
David L Wyles, Minhee Kang, Roy M Matining, Robert L Murphy, Marion G Peters

Open Forum Infect Dis· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1.
Jeffrey M Jacobson, Steven E Bosinger, Minhee Kang, Pablo Belaunzaran-Zamudio, Roy M Matining

AIDS Res Hum Retroviruses· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.
Tess Petersen, Yu-Jin Lee, Anu Osinusi, Valerianna K Amorosa, Crystal Wang, Roy Matining

AIDS Res Hum Retroviruses· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Older age is associated with peripheral blood expansion of naïve B cells in HIV-infected subjects on antiretroviral therapy.
Puja Van Epps, Roy M Matining, Katherine Tassiopoulos, Donald D Anthony, Alan Landay

PLoS One· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
Jeffrey M Jacobson, Lu Zheng, Cara C Wilson, Pablo Tebas, Roy M Matining

J Acquir Immune Defic Syndr· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.
Mark S Sulkowski, Minhee Kang, Roy Matining, David Wyles, Victoria A Johnson

J Infect Dis· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.
Benigno Rodriguez, David M Asmuth, Roy M Matining, John Spritzler, Jeffrey M Jacobson

J Acquir Immune Defic Syndr· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy.
Babafemi Taiwo, Roy M Matining, Lu Zheng, Michael M Lederman, Charles R Rinaldo

J Antimicrob Chemother· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction.
Robert C Kalayjian, John Spritzler, Roy M Matining, Susan A Fiscus, Barry H Gross

AIDS· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
Babafemi Taiwo, Lu Zheng, Sebastien Gallien, Roy M Matining, Daniel R Kuritzkes

AIDS· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.
Pablo Tebas, William Keith Henry, Roy Matining, Deborah Weng-Cherng, John Schmitz

PLoS One· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis